PortfoliosLab logoPortfoliosLab logo
PBE vs. ENVB
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

PBE vs. ENVB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco Dynamic Biotechnology & Genome ETF (PBE) and Enveric Biosciences Inc (ENVB). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PBE achieves a 3.32% return, which is significantly higher than ENVB's -59.23% return. Over the past 10 years, PBE has outperformed ENVB with an annualized return of 8.90%, while ENVB has yielded a comparatively lower -74.86% annualized return.


PBE

1D
0.81%
1M
4.85%
YTD
3.32%
6M
5.17%
1Y
34.13%
3Y*
10.91%
5Y*
2.31%
10Y*
8.90%

ENVB

1D
-3.27%
1M
-34.22%
YTD
-59.23%
6M
-72.39%
1Y
-89.81%
3Y*
-87.52%
5Y*
-85.10%
10Y*
-74.86%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PBE vs. ENVB - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PBE
Invesco Dynamic Biotechnology & Genome ETF
3.32%24.84%1.10%3.71%-10.83%1.54%25.66%18.65%-0.19%22.28%
ENVB
Enveric Biosciences Inc
-59.23%-94.37%-72.43%-37.50%-95.53%-37.16%-34.51%-48.17%-94.37%-52.38%

Correlation

The correlation between PBE and ENVB is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.19

Correlation (3Y)
Calculated over the trailing 3-year period

0.19

Correlation (5Y)
Calculated over the trailing 5-year period

0.24

Correlation (10Y)
Calculated over the trailing 10-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Jan 4, 2016

0.18

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PBE vs. ENVB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PBE
PBE Risk / Return Rank: 5858
Overall Rank
PBE Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
PBE Sortino Ratio Rank: 6363
Sortino Ratio Rank
PBE Omega Ratio Rank: 5353
Omega Ratio Rank
PBE Calmar Ratio Rank: 6363
Calmar Ratio Rank
PBE Martin Ratio Rank: 5252
Martin Ratio Rank

ENVB
ENVB Risk / Return Rank: 1111
Overall Rank
ENVB Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
ENVB Sortino Ratio Rank: 1212
Sortino Ratio Rank
ENVB Omega Ratio Rank: 1212
Omega Ratio Rank
ENVB Calmar Ratio Rank: 22
Calmar Ratio Rank
ENVB Martin Ratio Rank: 1010
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PBE vs. ENVB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and Enveric Biosciences Inc (ENVB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PBEENVBDifference
Sharpe ratioReturn per unit of total volatility

+2.32

Sortino ratioReturn per unit of downside risk

+3.70

Omega ratioGain probability vs. loss probability

1.31

0.87

+0.44

Calmar ratioReturn relative to maximum drawdown

2.92

-0.98

+3.91

Martin ratioReturn relative to average drawdown

8.21

-1.34

+9.55

PBE vs. ENVB - Sharpe Ratio Comparison

The current PBE Sharpe Ratio is 1.81, which is higher than the ENVB Sharpe Ratio of -0.51. The chart below compares the historical Sharpe Ratios of PBE and ENVB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PBE vs. ENVB - Drawdown Comparison

The maximum PBE drawdown since its inception was -45.69%, smaller than the maximum ENVB drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for PBE and ENVB.


Loading charts...

Drawdown Indicators


PBEENVBDifference

Max Drawdown

Largest peak-to-trough decline

-45.69%

-100.00%

+54.31%

Max Drawdown (1Y)

Largest decline over 1 year

-11.73%

-91.49%

+79.76%

Max Drawdown (3Y)

Largest decline over 3 years

-22.43%

-99.81%

+77.38%

Max Drawdown (5Y)

Largest decline over 5 years

-34.71%

-100.00%

+65.29%

Max Drawdown (10Y)

Largest decline over 10 years

-37.84%

-100.00%

+62.16%

Current Drawdown

Current decline from peak

-1.00%

-100.00%

+99.00%

Average Drawdown

Average peak-to-trough decline

-16.21%

-86.07%

+69.86%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.17%

66.73%

-62.56%

Volatility

PBE vs. ENVB - Volatility Comparison

The current volatility for Invesco Dynamic Biotechnology & Genome ETF (PBE) is 6.04%, while Enveric Biosciences Inc (ENVB) has a volatility of 21.07%. This indicates that PBE experiences smaller price fluctuations and is considered to be less risky than ENVB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PBEENVBDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.04%

21.07%

-15.03%

Volatility (6M)

Calculated over the trailing 6-month period

13.67%

105.59%

-91.92%

Volatility (1Y)

Calculated over the trailing 1-year period

19.01%

175.01%

-156.00%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

22.48%

155.96%

-133.48%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

24.91%

164.65%

-139.74%

Dividends

PBE vs. ENVB - Dividend Comparison

PBE's dividend yield for the trailing twelve months is around 1.02%, while ENVB has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
ENVB
Enveric Biosciences Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PBE
Invesco Dynamic Biotechnology & Genome ETF
1.02%1.00%0.05%0.02%0.00%0.00%0.04%0.00%0.00%0.57%0.38%1.12%

Frequently Asked Questions


PBE and ENVB have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ENVB has higher volatility (21.07%) compared to PBE (6.04%). In terms of maximum drawdown, PBE dropped -45.69% vs ENVB's -100.00%.

PBE currently has the higher Sharpe Ratio (1.81 vs -0.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PBE and ENVB

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer